1. Introduction {#sec1-jof-04-00098}
===============

*Aspergillus* spp. are filamentous, environmental fungi that cause a wide spectrum of infections in humans, including hypersensitivity reactions, chronic pulmonary infections, and acute life-threatening infections, the latter occurring primarily in immunocompromised individuals \[[@B1-jof-04-00098],[@B2-jof-04-00098],[@B3-jof-04-00098],[@B4-jof-04-00098]\]. Of over 250 species of *Aspergillus*, fewer than 40 are known to cause infections in humans \[[@B5-jof-04-00098]\], and of these, *Aspergillus fumigatus* is the most common cause of infections in humans and is the most common cause of serious, invasive disease.

The 2017 global estimates indicated that more than 3,000,000 cases of chronic pulmonary aspergillosis (CPA), and ≈250,000 cases of invasive aspergillosis (IA) occur annually \[[@B6-jof-04-00098]\]. Prior population-based estimates of invasive aspergillosis (IA) in the 1990s suggest an annual incidence rate of 1 to 2 cases of aspergillosis per 100,000 population \[[@B7-jof-04-00098]\], although given the increasing number of solid organ transplant (SOT) and stem cell transplant (SCT) recipients, as well as the increased use of immunosuppression, this study likely underestimates the current incidence of IA. In high-risk populations, such as SCT recipients, the 12-month incidence of invasive fungal infections (IFIs) is 3.4%, with IA causing around half of those infections \[[@B3-jof-04-00098]\]. In SOT recipients, the annual incidence of IA was 0.65% in one large study \[[@B8-jof-04-00098]\].

IA most commonly involves the lungs, where individuals present with signs and symptoms of pneumonia including fever, chest pain, and hemoptysis, although other organ systems may be involved. Diagnostic modalities are evolving, but *Aspergillus* infections are most commonly diagnosed by culture, histopathology, or by galactomannan antigen detection in blood or bronchoalveolar lavage fluid (BALF). The optimal management of infections from IA includes prevention, early diagnosis, early initiation of antifungal therapy, reduction in immunosuppressive therapy if possible, and in some cases, surgery. Amphotericin B was an early treatment option for IA and its newer lipid-based formulations are still used in some instances, although newer options including voriconazole and isavuconazole are now often preferred.

CPA is progressing more slowly than IA and affects patients with pre-existing pulmonary pathology, such as active or previous tuberculosis and non-tuberculosis mycobacterial infection, previous surgery for lung cancer, chronic obstructive pulmonary disease (COPD), or sarcoidosis, although the later may also be at risk for IA due to concomitant immunosuppressive treatment \[[@B1-jof-04-00098],[@B9-jof-04-00098]\].

2. Clinical Manifestations and Diagnosis {#sec2-jof-04-00098}
========================================

IA is primarily found in the lungs but may disseminate to other organs. Signs and symptoms depend on which organs are affected, and may include cough, hemoptysis, dyspnea, chest pain, skin lesions, or neurological symptoms. Importantly, pathogenesis of IA and associated signs and symptoms, as well as radiological presentation and diagnostic test performance, differs markedly between patients with neutropenia (i.e., primarily angioinvasive growth) and non-neutropenic patients (i.e., primarily airway invasive growth) \[[@B10-jof-04-00098],[@B11-jof-04-00098]\]. While fever is present in \>95% of neutropenic patients with IA, it is present in only 50--70% of non-neutropenic patients with IA \[[@B12-jof-04-00098]\], and cough and chest pain may be less frequently observed in non-neutropenic patients \[[@B12-jof-04-00098]\]. Radiological presentation in chest computed tomography (CT) differs by neutrophil count, with "typical" signs of IA including the halo sign or air crescent sign being frequently observed in neutropenic patients, while non-specific infiltrates or consolidations are most frequently observed in non-neutropenic patients \[[@B13-jof-04-00098],[@B14-jof-04-00098]\]. Strikingly, "typical" radiologic signs, as defined by consensus definitions of IA, are present in only 30--50% of non-neutropenic proven IA cases \[[@B13-jof-04-00098]\]. As a consequence, IA remains difficult to diagnose, particularly in non-neutropenic patients where clinical presentation and radiological signs are mostly atypical. Therefore, diagnosis of IA is often delayed, and IA remains associated with high mortality rates of around 30--40% \[[@B15-jof-04-00098]\].

Due to the absence of a single "gold standard" test for the diagnosis of IA, different mycological assays are employed and combined with clinical, radiological, and histological methods. Mycological diagnostic approaches for IA include fungal culture from BALF and biopsies; immunodetection of the cell wall component galactomannan (GM) in serum, BALF, and urine; detection of the cell wall component 1,3-β-[d]{.smallcaps}-glucan (BDG) via factor G activation in serum; detection of *Aspergillus*-specific siderophores in BALF or urine; detection of an *Aspergillus*-specific cell wall protein via a lateral flow device test (LFD); and detection of *Aspergillus*-specific DNA via PCR in blood and BALF \[[@B16-jof-04-00098],[@B17-jof-04-00098],[@B18-jof-04-00098],[@B19-jof-04-00098],[@B20-jof-04-00098],[@B21-jof-04-00098],[@B22-jof-04-00098],[@B23-jof-04-00098],[@B24-jof-04-00098],[@B25-jof-04-00098],[@B26-jof-04-00098],[@B27-jof-04-00098],[@B28-jof-04-00098],[@B29-jof-04-00098],[@B30-jof-04-00098],[@B31-jof-04-00098],[@B32-jof-04-00098],[@B33-jof-04-00098]\]. The most commonly used non-culture-based approach for IA diagnosis is GM detection in serum and BALF. In contrast to BALF GM detection, performance of serum GM is heavily influenced by neutrophil status of the host with sensitivities over 60--70% in neutropenic patients with angioinvasive growth but sensitivities are often \<20% in non-neutropenic patients with airway invasive growth \[[@B34-jof-04-00098],[@B35-jof-04-00098],[@B36-jof-04-00098]\]. Another factor that reduces sensitivities of all diagnostic tests for IA, including culture, GM, PCR, and LFD is ongoing mold-active antifungal prophylaxis or treatment \[[@B37-jof-04-00098],[@B38-jof-04-00098],[@B39-jof-04-00098],[@B40-jof-04-00098]\]. Given the reduced sensitivities of all available diagnostic tests in patients receiving mold-active antifungals, combination of multiple diagnostic tests and biomarkers from BALF and blood is the currently recommended approach, and has been shown to be associated with a significant increase of sensitivities, while specificities were only reduced slightly \[[@B19-jof-04-00098],[@B20-jof-04-00098],[@B23-jof-04-00098],[@B30-jof-04-00098],[@B32-jof-04-00098],[@B41-jof-04-00098],[@B42-jof-04-00098],[@B43-jof-04-00098]\]. The most promising combinations include PCR and/or the *Aspergillus*-specific LFD and/or GM from BALF with serum GM and/or very high levels of serum interleukin 8, which has recently been shown to be highly sensitive and specific when combined with BALF LFD or PCR \[[@B19-jof-04-00098],[@B22-jof-04-00098],[@B23-jof-04-00098],[@B26-jof-04-00098],[@B27-jof-04-00098],[@B30-jof-04-00098],[@B32-jof-04-00098],[@B33-jof-04-00098]\].

CPA is characterized by slowly progressive destruction of lung parenchyma, in the form of single of multiple cavities, nodules, infiltrates, or fibrosis, with or without an aspergilloma \[[@B2-jof-04-00098]\]. Due to the nonspecific and indolent presentation, diagnosis may be delayed or missed, resulting in severe morbidity. Diagnostic criteria include presence of respiratory and/or constitutional symptoms for at least 3 months, suggestive abnormalities on imaging, and serological or microbiological evidence of *Aspergillus* \[[@B44-jof-04-00098]\]. For mycological evidence, *Aspergillus* specific IgG has a central role, while biomarkers and tests for invasive growth, including GM, are mostly negative \[[@B44-jof-04-00098],[@B45-jof-04-00098]\].

3. Treatment of *Aspergillus* Infections {#sec3-jof-04-00098}
========================================

3.1. Treatment of Invasive Aspergillosis {#sec3dot1-jof-04-00098}
----------------------------------------

Early systemic antifungal treatment is of primary importance for survival against IA, while surgery plays an important role mainly in rarer disease manifestations of invasive disease including, e.g., sinusitis and osteomyelitis. Pharmacokinetic characteristics of broad-spectrum triazoles, liposomal amphotericin B, and echinocandins are reviewed in [Table 1](#jof-04-00098-t001){ref-type="table"}. The indications for surgery for IA have been extensively reviewed before \[[@B46-jof-04-00098]\]. The same applies to CNS infections and endophthalmitis where drug penetration considerations are particularly important (see also [Table 1](#jof-04-00098-t001){ref-type="table"}) \[[@B47-jof-04-00098]\].

### 3.1.1. Amphotericin B {#sec3dot1dot1-jof-04-00098}

Intravenous (IV) amphotericin B, a polyene, binds to ergosterol in fungal membranes forming pores and leading to cell death. It is used to treat a number of fungal infections, including IA, mucormycosis, cryptococcal meningitis, and invasive candidiasis. Investigation of liposomal amphotericin B (L-AmB) has shown a positive correlation between in-vitro susceptibility testing and positive clinical outcomes in patients with IA. In a study of 29 patients with IA following SCT, all six patients with a mean inhibitory concentration (MIC) of \<2 mg/L to L-AmB survived, while 22/23 patients with isolates with an MIC ≥2 mg/L died \[[@B53-jof-04-00098]\]. Another study using a pharmacokinetic-pharmacodynamic (PK-PD) model simulating free amphotericin B serum concentrations found the estimated breakpoints for susceptibility, intermediate susceptibility, and resistance for *A. fumigatus* to be ≤0.5, 1, and ≥2, respectively \[[@B54-jof-04-00098]\]. Overall, L-AmB remains sensitive against most *Aspergillus* spp., although increasing rates of elevated MICs \>2 have recently been reported for *Aspergillus fumigatus* (\>40% of isolates MICs \>2), and *Apergillus flavus* (\>80% of isolates) \[[@B55-jof-04-00098]\]. *Aspergillus terreus* shows intrinsic resistance \[[@B56-jof-04-00098]\].

In a prospective, randomized, multicenter trial of patients with either hematologic malignancy or status post SCT, patients were given either L-AmB at 1 mg/kg or L-AmB at 4 mg/kg daily. Of 87 evaluable patients, there was no difference in radiologic response, 6-month survival rates, or deaths between the two groups. The six-month survival rate was around 40% in both groups, with about 50% of those deaths thought to be related to IA \[[@B57-jof-04-00098]\]. Another multi-center randomized trial investigated L-AmB at either 3 mg/kd/day or 10 mg/kg/day for 14 days followed by 3 mg/kg per day. The vast majority of patients in this study had underlying hematologic malignancy and IA accounted for 97% of invasive fungal infections. There was no difference in clinical response or survival between the two groups, with clinical response in 50% of patients and 12-week survival of 72% in the 3 mg/kg per day cohort \[[@B58-jof-04-00098]\]. In a pooled analysis of published trials investigating L-AmB for the treatment of IA and other filamentous fungal infections in immunocompromised individuals, favorable response rates were observed in about 51% of cases of probable or proven invasive fungal infections \[[@B59-jof-04-00098]\]. While L-AmB remains an important agent for treatment of IA and other invasive mold infections \[[@B60-jof-04-00098]\], high rates of toxicity and side effects from L-AmB, including infusion-related reactions, phlebitis during infusion, gastrointestinal side effects such as diarrhea, nausea, and vomiting, transaminitis, electrolyte derangements, and nephrotoxicity have led to the investigation of other, better tolerated agents \[[@B61-jof-04-00098]\].

### 3.1.2. Azoles {#sec3dot1dot2-jof-04-00098}

Broad-spectrum triazoles inhibit ergosterol synthesis in the membrane sterol of fungi leading to cell death. Several of the newer-generation triazoles, particularly voriconazole and isavuconazole, are appealing alternatives to the use of L-AmB. While azole resistant clinical *Aspergillus* isolates have been reported from many parts of the world, resistance rates remain low in most settings, not influencing primary choice of antifungal therapy \[[@B62-jof-04-00098]\]. Pharmacokinetics of a broad spectrum differ significantly, and intra- and interpatient variability of plasma levels, but also variability in intracellular concentrations remains an issue \[[@B63-jof-04-00098]\]. Therapeutic drug monitoring (TDM) may be required to achieve efficacy and also to avoid toxicity in particular for voriconazole in treatment and prophylactic settings \[[@B64-jof-04-00098],[@B65-jof-04-00098],[@B66-jof-04-00098]\], but also for posaconazole oral suspension (efficacy only) \[[@B67-jof-04-00098],[@B68-jof-04-00098],[@B69-jof-04-00098]\], which is associated with significantly lower posaconazole plasma concentrations when compared to tablet or IV formulations \[[@B70-jof-04-00098]\], while there are currently no recommendations of TDM for isavuconazole \[[@B63-jof-04-00098],[@B71-jof-04-00098]\].

Voriconazole, available in tablet, IV, and suspension formulation, is approved for the treatment of IA, *Candida* infections, scedosporiosis, and furasiosis. A prospective randomized trial in patients with underlying hematologic disease and IA investigated 144 patients randomized to receive IV voriconazole and 133 patients randomized to receive IV amphotericin B deoxycholate. The primary outcome was partial or complete response to therapy. At twelve weeks, 52.8% of patients met the primary outcome in the voriconazole group (a complete response of 20.8% and a partial response of 31.9%) versus 31.6% in the amphotericin group (a complete response of 16.5% and a partial response of 15.0%), a statistically significant difference. At 12 weeks, the survival rate was 70.8% in the voriconazole group versus 57.9% in the amphotericin group, which again was statistically significant. In addition, there were fewer drug-related adverse events in the voriconazole group, although side effects to treatment, such as blurry vision and photophobia, were common \[[@B72-jof-04-00098]\]

Isavuconazole, available in capsule and IV formulation, is another triazole preferred for the treatment of IA \[[@B63-jof-04-00098],[@B73-jof-04-00098],[@B74-jof-04-00098],[@B75-jof-04-00098]\]. In the large randomized SECURE trial, 527 patients with invasive mold infection were randomized to receive either IV isavuconazole followed by IV or oral (PO) isavuconazole versus IV voriconazole followed by IV or PO voriconazole. The majority of patients in both groups had underlying hematologic malignancy (82% in the isavuconazole group versus 86% in the voriconazole group). The primary endpoint was all-cause mortality at 6 weeks and *Aspergillus* spp were the cause of infection in 30% of patients in both groups. At 6 weeks, 19% of patients in the isavuconazole group died compared to 20% in the voriconazole group, a difference that did not meet statistical significance. Drug-related adverse events were significantly higher in the voriconazole group compared to the isavuconazole group (60% versus 42%, *p* \< 0.001), and permanent drug discontinuation was lower in the isavuconazole group compared to the voriconazole group (8% versus 14%) \[[@B76-jof-04-00098]\].

A number of studies have suggested that posaconazole, available in delayed-release tablets, oral suspension, and IV formulation, may be an option to treat refractory IA \[[@B77-jof-04-00098]\]. An open-labeled trial investigated the use of posaconazole as a salvage therapy for the treatment of IA in patients that were refractory or intolerant to other treatment, of which 80% of patients had underlying hematologic malignancy. Of 107 patients who received posaconazole oral suspension, 42% had a treatment response compared to 26% of the 86 external control patients (*p* = 0.006) \[[@B78-jof-04-00098]\]. In another prospective trial of patients with refractory IA, 53 patients received posaconazole given orally or via an enteral feeding tube, 52 received lipid formulation of amphotericin B (LPD/AMB), and 38 patients received a combination of caspofungin plus LPD/AMB. The primary outcome was clinical improvement or resolution at 12 weeks and over 90% of patients had underlying hematologic malignancy. The primary outcome was met in 40% of patients in the posaconazole group, 8% in the LPD/AMB group, and 11% in the combination group (*p* \< 0.002). At 12 months, 40% of patients died in the posaconazole group compared to 65% in the LPD/AMB group and 68% in the combination group (*p* \< 0.008) \[[@B79-jof-04-00098]\].

### 3.1.3. Echinocandins {#sec3dot1dot3-jof-04-00098}

The echinocandins, which inhibit β-1,3-glucan synthesis in the cell wall of fungi, have also been investigated for the treatment of IA. In an open-labeled, non-randomized, single-arm study, patients with IA following SCT were given at least 15 days of IV caspofungin (a median duration of 24 days). The primary endpoint was partial or complete clinical response. Enrollment was stopped early due to slow enrollment and the study was under-powered. At 12 weeks, 8 patients (33%) had complete or partial response to therapy and survival at 6 and 12 weeks was 79% and 50%, respectively \[[@B80-jof-04-00098]\]. In another open-label, non-randomized, single-arm study, patients with underlying hematologic malignancy or following SCT were given at least 15 days of caspofungin (a median duration of 27 days). The primary endpoint was partial or complete clinical response. At the end of treatment 1 patient (1/61) had a complete response to treatment and 19 patients (19/61) had a partial response. At 6 and 12 weeks the survival rate was 66% and 53%, respectively. Patients were not followed beyond 12 weeks \[[@B81-jof-04-00098]\]. Lastly, another study looked at caspofungin for the treatment of refractory IA and compared treatment responses to a historical cohort. The majority of patients had underlying hematologic disease. Of 83 patients who received caspofungin, 45% experienced a complete or partial clinical response to treatment, compared to a 16% response rate in the historical cohort, of which the majority received amphotericin B with or without itraconazole \[[@B82-jof-04-00098]\].

### 3.1.4. Combination Therapy {#sec3dot1dot4-jof-04-00098}

In a large randomized, double-blind, placebo-controlled multicenter trial, 454 patients with hematological malignancies and suspected or documented IA were randomly assigned to primary treatment with voriconazole and anidulafungin or voriconazole and placebo. Primary analysis was done in the modified intention-to-treat population of 277 patients in whom IA was confirmed. Mortality rates at 6 weeks were 19.3% for combination therapy and 27.5% for monotherapy (difference, −8.2 percentage points \[95% CI, −19.0 to 1.5\]; *p* = 0.087). In a post hoc analysis of 218 patients who had IA diagnosis established by radiographic findings and galactomannan positivity, 6-week mortality was lower in combination therapy than monotherapy (15.7% vs. 27.3%; difference, −11.5 percentage points \[CI, −22.7 to −0.4\]; *p* = 0.037) \[[@B83-jof-04-00098]\]. While the study was insufficiently powered to detect a difference in the main analysis, results indicate that combination therapy may be associated with better survival \[[@B83-jof-04-00098]\].

A multinational, open-label, non-comparative study investigated IV micafungin, alone or in combination with other agents, for the treatment of IA. The primary outcome was partial or complete clinical response. Of 225 patients who met inclusion criteria, the majority were SCT recipients or had an underlying hematologic malignancy. Of those who received micafungin as primary therapy, 17/29 received combination therapy, with 2/17 experiencing a complete response to treatment and 3/17 a partial response (total response of 29%); 12/29 received monotherapy with micafungin with 0% experiencing a complete response and 6/12 experienced a partial response (a total response of 50%). Of those who received micafungin as salvage therapy, 174/196 received combination therapy with 13/174 experiencing a complete response and 47/174 a partial response (a total response of 34.5%); 22/196 received micafungin monotherapy with 3/22 experiencing a complete response and 6/22 a partial response (a total response of 41%) \[[@B84-jof-04-00098]\]. An open-label, non-comparative study of SCT recipients investigated micafungin alone or in combination with other agents for the treatment of IA. Most patients (89%) had refractory IA that did not respond to initial first-line therapy. The primary endpoint was response to therapy. Of 98 patients, 8 (8%) received micafungin monotherapy with a treatment response rate of 38% (3/8). Of 90 patients (92%) who were treated with combination therapy, the treatment response rate was 24% (22/90), with all but one of those treatment responses being in patients with refractory IA \[[@B85-jof-04-00098]\].

Another study investigated caspofungin in combination with other agents for the treatment of refractory IA. Of 53 patients, 30% (16/53) received caspofungin plus amphotericin B and 70% (37/53) received caspofungin plus a triazole. Partial or complete resolution at the end of therapy and at Day 84 was 55% (29/53) and 49% (25/51), respectively. Survival at Day 84 was 55% \[[@B86-jof-04-00098]\]. Lastly, another study looked at voriconazole plus caspofungin for the primary treatment of IA in SOT recipients and compared outcomes to a historical cohort of SCT recipients who received LPD/AMB. At 90 days, survival was 67.5% (27/40) in the combination therapy group versus 51% (24/47) in the historical control group (*p* = 0.117) \[[@B87-jof-04-00098]\].

### 3.1.5. Guideline Recommendations {#sec3dot1dot5-jof-04-00098}

Current recommendations are summarized in [Table 2](#jof-04-00098-t002){ref-type="table"}. The Infectious Diseases Society of America (IDSA) 2016 guidelines recommend voriconazole as first-line treatment for IA (AI recommendation) with liposomal amphotericin B and isavuconazole as alternative options (AII recommendation). L-AmB is an option for salvage therapy (AII recommendation) \[[@B88-jof-04-00098]\]. The more recently updated guidelines of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM), as well as the guidelines of the European Conference on Infections in Leukemia (ECIL-6), both recommend voriconazole and isavuconazole as the preferred agents for the treatment of IA in patients with underlying hematologic malignancy (AI---AII recommendation and A1 recommendation, respectively). The ESCMID/ECMM 2017 and ECIL-6 recommend L-AmB as a second-line option (BII and BI recommendation, respectively) 1\]. While the IDSA does not recommend primary therapy with an echinocandin (AII), ESCMID/ECMM and ECIL-6 only marginally recommend primary treatment with an echinocandin (CII recommendations).

The IDSA gives combination treatment with voriconazole and an echinocandin a weak recommendation, offering consideration for this approach in select patients (CII recommendation). In line, ESCMID/ECMM 2017 and ECIL-6 both only marginally recommend combination antifungal therapy with voriconazole plus an echinocandin for the primary treatment of IA (CI recommendation). Posaconazole is given a BII grade by both the ESCMID/ECMM 2017 and ECIL-6 and is recommended by the IDSA for use as a salvage therapy for IA (AII recommendation). In addition, the ESCMID/ECMM recommends voriconazole as a first-line treatment of IA in patients without hematologic malignancies (AIII recommendation). The IDSA recommends that antifungal therapy be continued for a minimum of 6--12 weeks, with duration based on factors such as severity of infection, duration of immunosuppression, and response to therapy. The ESCMID/ECMM recommends treatment duration be based primarily on treatment response and immune reconstitution.

While currently available guidelines are targeted towards a small number of high-resource countries, they mostly fail to provide guidance for low- and middle-income countries (LMICs). This will be changed by the "One World--One Guideline" initiative, which has been spearheaded by the European Confederation of Medical Mycology and has the goal to unify the medical mycology community, by creating guidelines that are applicable worldwide including low- and middle-income countries \[[@B71-jof-04-00098]\].

### 3.1.6. Azole Resistance in *Aspergillus Fumigatus* {#sec3dot1dot6-jof-04-00098}

Although voriconazole and isavuconazole are the first-line agents for the treatment of IA, resistance to these agents is emerging \[[@B89-jof-04-00098]\]. A single-center study in Brazil investigated susceptibility profiles for *Aspergillus* isolates, of which *A. fumigatus* represented 74% of the 228 isolates. Nine patients showed high MIC values to at least one azole, although none showed complete resistance. Of additional concern, 43% of *A. fumigatus* isolates had an MIC \>2 mg/L to amphotericin B, an important option for treatment of refractory IA \[[@B56-jof-04-00098]\]. In a 2016 nationwide survey of Dutch Hematology Centers, of 784 patients in which *A. fumigatus* was isolated, 101 isolates (12.9%) showed resistance to triazoles, an increase from 10.7% of isolates in 2015 and 7.2% of isolates in 2014. Among individual Hematology Centers, resistance ranged from 9.5% to 20.5%. This increasing resistance to triazoles is thought to be due to the environmental use of azole fungicides. Because of high local resistance to triazoles in one Dutch Hematology Center, L-AmB is frequently used as first-line therapy for IA \[[@B90-jof-04-00098]\]. Another Dutch cohort study found that triazole resistance was found in 23/144 (16%) of patients with influenza-associated IA, and that the detection of resistance to voriconazole was highly associated with treatment failure \[[@B91-jof-04-00098]\]. Thus, there is a clear need for continued vigilance for triazole-resistant strains of *A. fumigatus*.

### 3.1.7. New Agents to Treat Invasive Aspergillosis {#sec3dot1dot7-jof-04-00098}

While there has been substantial improvement in treatment of IA, associated with decreasing mortality rates, more targeted methods may help to further decrease morbidity and mortality. There are a number of promising new therapies under development for the treatment of IA. A novel echinocandin, Biafungin (CD101), is currently under investigation in pre-clinical studies and showed early promise in mouse models as a once-weekly dosing option for the prevention and treatment of some IFIs, including IA \[[@B92-jof-04-00098]\]. Other agents are under investigation in clinical trials, some with novel mechanisms of action. E1210 (Eisai Company, Tokyo, Japan) is investigating a novel agent that targets the glycosylphosphatidylinositol (GP1) protein in the cell wall leading to the arrest of fungal growth. E1210 was promising in pre-clinical studies with in vitro activity against most yeast and molds including *A. fumigatus* and is entering phase I clinical trials \[[@B93-jof-04-00098]\]. F901318 (FTG Ltd., Cheshire, United Kingdom) targets pyrimidine biosynthesis and has shown in vitro activity against triazole-resistant molds such as *A. fumigatus*, *Scedosporium* spp., and *Fusarium* spp. in Phase I study \[[@B94-jof-04-00098]\]. Phase II studies are currently ongoing. ASP2397 (Vical Inc., San Diego, CA, USA) is a novel agent that inhibits aluminum iron chelation and has shown promise in Phase I clinical trials against *Aspergillus* spp. \[[@B95-jof-04-00098]\].

3.2. Treatment of Chronic Pulmonary Aspergillosis {#sec3dot2-jof-04-00098}
-------------------------------------------------

In the only randomized-controlled trial of azole therapy (*n* = 17) versus supportive care (*n* = 14) there was a significant benefit from a six-month course of itraconazole 400 mg daily \[[@B96-jof-04-00098]\]. Consequently, triazoles including itraconazole and voriconazole are the treatment of choice for CPA, with AII recommendation in the guideline published by the ESCMID, the European Respiratory Society (ERS), and the ECMM and a strong recommendation in guideline published by the IDSA \[[@B44-jof-04-00098],[@B88-jof-04-00098]\]. Posaconazole (BII) can be used as an alternative \[[@B44-jof-04-00098]\].

4. Conclusions {#sec4-jof-04-00098}
==============

Infections caused by *Aspergillus* spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of IA in those patients most at risk for infection, IA is increasingly observed in other non-neutropenic patient groups, including critically-ill patients with influenza, patients with caspase recruitment domain family member 9 (CARD9) deficiency \[[@B97-jof-04-00098]\], or patients who receive biological therapies, such as tumor necrosis factor-α inhibitors, and new small molecule kinase inhibitors, such as ibrutinib \[[@B98-jof-04-00098]\]. Clinical presentations of IA in many of these patient groups are atypical and diagnosis remains challenging. Early and targeted systemic antifungal treatment remains the most important predictive factor for successful outcome in immunocompromised individuals, and recent guidelines recommend both voriconazole and isavuconazole for primary treatment of IA. Few studies evaluated treatment options for CPA, where long-term oral itraconazole or voriconazole remain the treatment of choice.
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AI

strong recommendation, high-quality evidence (IDSA); strong evidence and evidence from ≥1 RCT (ECIL-6); strong recommendation and evidence from ≥1 RCT (ESCMID)

AII

strong recommendation, moderate-quality evidence (IDSA); strong evidence and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); strong recommendation and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)

AIII

strong recommendation, low-quality evidence (IDSA); strong evidence and opinion from respected authorities (ECIL-6); strong recommendation and opinion of respected authorities (ESCMID)

BI

strong or moderate evidence and evidence from ≥1 RCT (ECIL-6); moderate support and evidence from ≥1 RCT (ESCMID)

BII

strong or moderate evidence and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); moderate support and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)

CI

weak recommendation, high-quality evidence (IDSA); insufficient evidence for efficacy and evidence from ≥1 RCT (ECIL-6); marginal support and evidence from ≥1 RCT (ESCMID)

CII

weak recommendation, moderate-quality evidence (IDSA); insufficient evidence for efficacy and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ECIL-6); marginal support and evidence from ≥1 non-randomized clinical trial, cohort, or case-controlled study (ESCMID)

CIII

weak evidence, low-quality evidence (IDSA); insufficient evidence for efficacy and opinion from respected authorities (ECIL-6); marginal support and evidence of respected authorities (ESCMID)

DIII

moderate evidence against efficacy and opinion from respected authorities (ECIL-6); recommendation against use and evidence of respected authorities (ESCMID)
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###### 

Pharmacokinetic Characteristics of Broad-Spectrum Triazoles, Liposomal Amphotericin B, and Echinocandins \[[@B48-jof-04-00098],[@B49-jof-04-00098],[@B50-jof-04-00098],[@B51-jof-04-00098],[@B52-jof-04-00098]\].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                        Voriconazole                                          Isavuconazole                                           Posaconazole                                                      Liposomal Amphotericin B                    Caspofungin                                        Anidulafungin
  --------------------- ----------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------- -------------------------------------------------- -----------------------------------------------------
  **Dosage**            IV: 6 mg/kg Q12 × 24 h, 4 mg/kg Q12 starting Day 2\   IV: 200 mg Q8 h × 48 h, 200 mg daily starting Day 3\    IV: 300 mg Q12 × 24 h, 300 mg daily starting Day 2\               IV: 3 mg/kg/day                             70 mg daily on Day 1, 50 mg daily starting Day 2   200 mg daily on Day 1, 100 mg starting Day 2
                        PO: 200 mg Q12 h                                      PO: 200 mg Q8 h for 48 h, 200 mg daily starting Day 3   Delayed-release: 300 mg Q12 ×24 h, 300 mg daily starting Day 2\                                                                                                  
                                                                                                                                      Oral suspension: 200 mg TID                                                                                                                                      

  **Formulation**       PO, IV                                                PO, IV                                                  PO, IV                                                            IV                                          IV                                                 IV

  **Half-Life (h)**     6                                                     110--115                                                27--35                                                            7--10                                       9--11                                              24--26

  **Bioavailability**   Oral, 96%                                             Oral, 98%                                               Tablet: 54%Oral suspension: Variable                              Oral, 9%                                    Oral, \<5%                                         Oral, \<5%

  **Linear PK**         No                                                    High                                                    IV: NoSuspension/Tablet: High                                     Yes, doses 1--3 mg/kg; No at higher doses   Yes (Animal Model)                                 Yes (Animal Model)

  **Renal Excretion**   2%                                                    \<1%                                                    \<1%                                                              4.5%                                        41%                                                \<1%

  **CNS Penetration**   High                                                  High (Animal Model)                                     Low                                                               High (Animal Model)                         Low (Animal Model)                                 Low (Animal Model)

  **Metabolism**        CYP2C19, CYP2C9, CYP3A4                               CYP3A4/5                                                UGT                                                               Unknown                                     Hydrolysis and *N*-acetylation                     Spontaneous biotransformation into inactive peptide
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

jof-04-00098-t002_Table 2

###### 

Recommendations for the Treatment of Invasive Pulmonary Aspergillosis.

  ------------------------------------------------------------------------------------------ ----------------------------- -------------------- -------------- -------------------------- -----------------------
  **Targeted Treatment of Invasive Pulmonary Aspergillosis in Hematologic Malignancy**                                                                                                    
                                                                                             Voriconazole                  Isavuconazole        Itraconazole   Liposomal Amphotericin B   Echinocandins
  **ECIL-6 (61)**                                                                            AI                            AI                   CIII           BI                         CII
  **ESCMID (60)**                                                                            AI-AII                        AI-AII               CII-CIII       BII                        CII-CIII
  **IDSA (83)**                                                                              AI                            AII                  \-             AII                        AII (not recommended)
  **Salvage Treatment for Invasive Pulmonary Aspergillosis in Hematologic Malignancy**                                                                                                    
                                                                                             Voriconazole                  Isavuconazole        Itraconazole   Liposomal Amphotericin B   Posaconazole
  **ECIL-6 (61)**                                                                            BII                           BII                  CIII           BII                        BII
  **ESCMID (60)**                                                                            AII                           AII                  CII-DIII       BII                        BII
  **IDSA (83)**                                                                              \-                            \-                   AII            AII                        AII
  **Combination Treatment for Invasive Pulmonary Aspergillosis in Hematologic Malignancy**                                                                                                
                                                                                             Voriconazole + Echinocandin   Other combinations                                             
  **ECIL-6 (61)**                                                                            CI                            CIII                                                           
  **ESCMID (60)**                                                                            CI-CII                        DIII                                                           
  **IDSA (83)**                                                                              CII                           CII                                                            
  **Targeted Treatment of Chronic Pulmonary Aspergillosis**                                                                                                                               
                                                                                             Voriconazole                  Isavuconazole        Itraconazole   Liposomal Amphotericin B   Posaconazole
  **ECIL-6 (61)**                                                                            \-                            \-                   \-             \-                         \-
  **ESCMID (60)**                                                                            AII                           \-                   AII            \-                         BII
  **IDSA (83)**                                                                              \-                            \-                   Preferred      \-                         \-
  ------------------------------------------------------------------------------------------ ----------------------------- -------------------- -------------- -------------------------- -----------------------
